1149378-95-9

Basic information

• Product Name: 1-oxo-2,3-dihydro-1H-inden-5-yl benzoate
• Synonyms: 1-oxo-2,3-dihydro-1H-inden-5-yl benzoate
• CAS NO: 1149378-95-9
• Molecular Weight: 252.269
• Mol File: 1149378-95-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-oxo-2,3-dihydro-1H-inden-5-yl benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-oxo-2,3-dihydro-1H-inden-5-yl benzoate(1149378-95-9)
• EPA Substance Registry System: 1-oxo-2,3-dihydro-1H-inden-5-yl benzoate(1149378-95-9)

Safety Data

• Hazardous Substances Data: 1149378-95-9(Hazardous Substances Data)

Upstream product

• 1149378-96-0 1-hydroxy-2,3-dihydro-1H-inden-5-yl benzoate 
• 38005-82-2 2,3-dihydro-1H-indene-1,5-diol 
• 5111-70-6 5-methoxy-1-indanone 
• 3470-49-3 5-hydroxy-2,3-dihydro-1H-indene-1-one 
• 98-88-4 benzoyl chloride 

Relevant articles and documents

Kinetic resolution of racemic benzofused alcohols catalysed by HMFO variants in presence of natural deep eutectic solvents

5-Hydroxymethylfurfural oxidase (HMFO) has demonstrated to be a useful biocatalyst for the selective oxidation of alcohols employing oxygen as mild oxidant with no requirement of expensive organic cofactors. This wild-type HMFO biocatalyst and an engineered thermostable variant have been tested in the kinetic resolution of different benzofused alcohols. The use of natural deep eutectic solvents was also explored in HMFO-catalysed oxidation of alcohols. The oxidation of racemic 1-indanol showed a higher conversion and selectivity in presence of 60% v/v of different NADES, especially for those containing carbohydrates. By choosing properly the biocatalyst and the NADES, good enantioselectivity values can be obtained, demonstrating the advantages of employing these neoteric solvents in biocatalysed processes.

ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS

The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

ANTIDIABETIC TRICYCLIC COMPOUNDS

Tricyclic compounds containing a cyclopropanecarboxylic acid fused to a bicyclic ring, including pharmaceutically acceptable salts, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.